Bioblast Pharma Ltd. ORPN announced positive results from a phase IIa study on its lead candidate, trehalose, for the treatment of patients with spinocerebellar ataxia type 3 (SCA3). A look at ...

Today, I will be analyzing Bioblast Pharma Ltd’s (NASDAQ:ORPN) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a ...

Several months after abandoning plans for a securities offering, Israel’s Bioblast Pharma has asked JSB-Partners to help it seek out a partner or a merger to help lift it out of its troubles. In April ...

Company has said it needs new funding to complete the next stage of clinical testing for its only drug candidate (Getty Images) Israel's Bioblast Pharma has abandoned plans for a securities offering, ...

BioBlast paints a very optimistic picture of Cabaletta’s potential as an effective treatment for OPMD, but the data announced Tuesday are scant, cherry-picked and hardly conclusive.

Bioblast Pharma Ltd. CEO Colin Foster told BioWorld Today "it would not be unreasonable to think" that regulators could deem pivotal the upcoming phase IIb trial with trehalose in oculopharyngeal ...

Biocon founder and chairperson Kiran Mazumdar-Shaw plans a gradual leadership transition over the ‌next five years, with her niece Claire Mazumdar expected to take over as chair in a phased manner, ...

BioBlast Pharma announced promising results from a Phase 2 clinical study of its lead experimental drug to treat patients with rare muscle wasting disorder. The company said its lead drug in ...